TABLE 1.

Patient characteristics at baseline

ParameterValue for:
Evaluable populationSubset of patients with plasma piperaquine measurementsa
Total no. of patients598229
P. falciparum infection at enrolment
    No. (%) of patients342 (57)136 (59)
    Geometric mean parasitemia (organisms/μl−1) (95% CI)3,848 (3,198-4,632)3,631 (2,758-4,782)
    No. (%) of patients with parasitemia >1,000 organisms μl−1275 (80)111 (82)
P. vivax infection at enrolment
     No. of patients (%)173 (29)51 (22)
    Geometric mean parasitemia (organisms μl−1) (95% CI)1,988 (1,550-2,550)1,794 (1,168-2,757)
    No. (%) of patients with parasitemia >400 organisms μl−1136 (79)42 (82)
Mixed infections at enrolment
    No. (%) of patients83 (14)42 (18)
    Geometric mean parasitemia (organisms μl−1) (95% CI)4,717 (3,399-6,547)5,175 (3,269-8,193)
    No. (%) of patients with parasitemia >400 organisms μl−179 (95)40 (95)
No. (%) of males349 (58)145 (63)
Median wt (kg) (range)46 (7-85)52 (11-80)*
Median age (yr) (range)16 (1-60)20 (3-60)*
No. (%) of patients aged
    <5 yr96 (16)4 (1.7)
    5-14 yr178 (30)61 (27)
    >14 yr324 (54)164 (72)
No. (%) of patients with temp >37.5°C136 (23)53 (23)
No. (%) of patients with history of malaria in previous mo141 (24)45 (20)
Mean hemoglobin level (g/dl) (SD)10.2 (2.5)10.9 (2.4)*
No. (%) of patients with splenomegaly402 (67)139 (61)
  • a *, significant difference (P < 0.001) between subset of patients with plasma piperaquine measurement and the whole cohort.